Pacira CMO sells 3,040 shares under 10b5-1 plan

Pacira BioSciences, Inc. (PCRX) reported that its Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026 at $23.23 per share in an open-market transaction.

Rhea-AI Filing Summary

Pacira BioSciences, Inc. (PCRX) reported that its Chief Medical Officer, Jonathan Slonin, sold 3,040 shares of common stock on August 17, 2026 at $23.23 per share in an open-market transaction. The sale was effected pursuant to a Rule 10b5-1 trading plan adopted on August 12, 2025. Following this sale, Slonin directly holds 216,383.646 shares of Pacira common stock, which include 511.471 shares acquired through the company’s employee stock purchase plan in June 2026.

Insider Trade Summary 10b5-1

Net Seller: 3,040 shares

Net Sell 1 txn

Insider SLONIN JONATHAN

Role Chief Medical Officer

Sold 3,040 shs ($71K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2	3,040	$23.23	$71K

Holdings After Transaction: Common Stock — 216,383.646 shares (Direct)

Footnotes (2)

1. F1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.
2. F2. Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.

Key Figures

Shares sold: 3,040 shares Sale price per share: $23.23 per share Shares held after transaction: 216,383.646 shares +2 more

5 metrics

Shares sold 3,040 shares Common stock sale on August 17, 2026

Sale price per share $23.23 per share Price for the 3,040 shares of common stock sold

Shares held after transaction 216,383.646 shares Direct Pacira common stock holdings following the sale

ESPP shares included in holdings 511.471 shares Shares acquired under employee stock purchase plan in June 2026

Net shares sold 3,040 shares Net buy/sell shares as summarized in Form 4 transaction data

Key Terms

Rule 10b5-1 trading plan, employee stock purchase plan, Securities Exchange Act of 1934

3 terms

Rule 10b5-1 trading plan regulatory

"The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

employee stock purchase plan financial

"Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Securities Exchange Act of 1934 regulatory

"in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Pacira BioSciences (PCRX) report for Jonathan Slonin?

Pacira BioSciences reported that Chief Medical Officer Jonathan Slonin sold 3,040 shares of common stock on August 17, 2026 at $23.23 per share, in an open-market transaction under a Rule 10b5-1 trading plan.

Was the recent PCRX insider sale by Jonathan Slonin under a Rule 10b5-1 plan?

Yes. The sale was made under a Rule 10b5-1 trading plan that Jonathan Slonin adopted on August 12, 2025, providing for pre-arranged, automated trades in accordance with SEC Rule 10b5-1 of the Securities Exchange Act of 1934.

At what price were the Pacira BioSciences (PCRX) shares sold by Jonathan Slonin?

Jonathan Slonin sold 3,040 Pacira shares at a price of $23.23 per share. This was a sale of common stock in an open-market or private transaction as described in the Form 4 filing.

How many Pacira BioSciences (PCRX) shares does Jonathan Slonin hold after this transaction?

After the sale, Jonathan Slonin directly holds 216,383.646 shares of Pacira common stock. This total includes 511.471 shares acquired through Pacira’s employee stock purchase plan in June 2026.

How many Pacira BioSciences (PCRX) shares did Jonathan Slonin acquire through the employee stock purchase plan?

Jonathan Slonin acquired 511.471 shares of Pacira common stock under the company’s employee stock purchase plan in June 2026, and these shares are included in his post-transaction direct holdings.

What is the net effect of Jonathan Slonin’s recent Form 4 transaction in Pacira BioSciences (PCRX)?

The reported activity reflects a net sale of 3,040 shares of Pacira common stock. Following this transaction, Slonin’s direct ownership stands at 216,383.646 shares, as disclosed in the Form 4 summary data.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 05:21 PM Accepted by SEC EDGAR 08/18/2026 - 05:21 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SLONIN JONATHAN

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/17/2026		S(1)		3,040	D	$23.23	216,383.646(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on August 12, 2025.

2. Includes 511.471 shares of common stock acquired under the issuer's employee stock purchase plan in June 2026.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)